WO2019149922A1 - Compounds which cause degradation of egfr, for use against cancer - Google Patents

Compounds which cause degradation of egfr, for use against cancer Download PDF

Info

Publication number
WO2019149922A1
WO2019149922A1 PCT/EP2019/052585 EP2019052585W WO2019149922A1 WO 2019149922 A1 WO2019149922 A1 WO 2019149922A1 EP 2019052585 W EP2019052585 W EP 2019052585W WO 2019149922 A1 WO2019149922 A1 WO 2019149922A1
Authority
WO
WIPO (PCT)
Prior art keywords
piperidyl
oxo
isoindolin
dioxo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2019/052585
Other languages
French (fr)
Inventor
Martin Duplessis
Georg Jaeschke
Bernd Kuhn
Kiel LAZARSKI
Yanke LIANG
Yvonne Alice Nagel
Antonio Ricci
Daniel Rueher
Sandra Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hoffmann La Roche Inc
C4 Therapeutics Inc
Original Assignee
F Hoffmann La Roche AG
Hoffmann La Roche Inc
C4 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Hoffmann La Roche Inc, C4 Therapeutics Inc filed Critical F Hoffmann La Roche AG
Priority to EP19702906.9A priority Critical patent/EP3749664A1/en
Priority to JP2020541782A priority patent/JP2021525219A/en
Priority to CN201980009141.0A priority patent/CN111615512A/en
Publication of WO2019149922A1 publication Critical patent/WO2019149922A1/en
Priority to US16/984,987 priority patent/US20200361930A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the present compounds are useful for the therapeutic and/or prophylactic treatment of cancer.
  • heteroaryl denotes a monovalent aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms, comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon.
  • Particular“heteroaryl” have 6 rings atoms, comprising one N.
  • the terms“treating”,“contacting” and“reacting” when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
  • the invention also provides pharmaceutical compositions, methods of using, and methods of preparing the aforementioned compounds. All separate embodiments may be combined.
  • R 1 is H
  • B is aryl, in particular phenyl, which aryl is
  • Ci_ 6 alkyl in particular methyl, and iii. hydroxy.
  • E7 Use of the compound as described herein, or pharmaceutically acceptable salts thereof, for the therapeutic and/or prophylactic treatment of cancer.
  • E8 A pharmaceutical composition comprising a compound as described herein, and a therapeutically inert carrier.
  • E9 A certain embodiment of the invention refers to the compound of formula I, or pharmaceutically acceptable salts thereof, as described herein, for use as medicament.
  • a certain embodiment of the invention relates to the compound of formula I as described herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of cancer.
  • a certain embodiment of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the compound of formula I as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary substance.
  • the compounds of formula I may contain one or more asymmetric centers and can therefore occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within this invention. The present invention is meant to encompass all such isomeric forms of these compounds. The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein.
  • Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
  • racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
  • An isoindoline-acetylene based compound of general formula I can be obtained for example by amide coupling with an appropriately substituted acid of formula 1 and an appropriately substituted amine of formula 2 with a coupling agent such as TBTU to yield the desired amide derivatives of formula 3.
  • a coupling agent such as TBTU
  • Deprotection followed by ring cyclization with a iodo or bromo substituted methyl 2-(bromomethyl)benzoate of formula 5 yields the desired isoindoline 6.
  • Sonogashira coupling with an appropiate substituted acetlyne of formula 7 forms the desired isoindoline-acetylene based compound of general formula I (scheme 1).
  • the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent.
  • an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like.
  • the temperature is maintained between 0 °C and 50 °C.
  • the resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.
  • the compounds of general formula I in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • EGFR degradation was determined based on quantification of FRET signal using EGFR total kit.
  • the FRET signal detected correlates with total EGFR protein level in cells.
  • test compounds were added to the 384-well plate from a top concentration of 1 pM with 11 points, half log titration in quadruplicates.
  • BaF3 EGFR mutant cell lines (EGFR T790M/L858R/C797S) were added into 384-well plates at a cell density of 10000 cells per well. The plates were kept at 37 °C with 5% C0 2 for 4 hours. After 4-hour incubation, 4X lysis buffer was added to the cells, and then then microplate was agitated on plate shaker at 500 rpm for 30 minutes at room temperature.
  • Step 1 tert-Butyl N-GP RS)-2-oxo-l -phenyl -2-fthi azol-2-ylam i no )cthyl1carbamatc
  • Step 4 tert-Butyl 4-rf4-cthvnvlphcnvl )mcthyl1pipcraz :- 1 -carboxyl ate
  • the crude product was purified by flash chromatography on a silica gel column eluting with a dichloromethane:methanol 100:0 to 90:10 gradient.
  • the desired tert-butyl 4-[[4-[2-[3-oxo-2- [(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]phenyl]methyl]piperazine-l-carboxylate (quantitative yield) was obtained as an orange solid, MS: m/e 646.6 (M+H + ).
  • Step 6 (2RS)-2-f 1 -Qxo-6-r2-r4-fnincrazin- 1 -ylmcthyl )nhcnyl1cthvnyl1isoindolin-2-yl1-2- phenyl-N-thiazol-2-yl-acetamide hydrochloride
  • Step 8 3RSV2.6-Dioxo-3-piperidvH-l.3-dioxo-isoindolin-4-
  • Step 1 Methyl 5-r2-r3-oxo-2-rnS -2-oxo-l-phenyl-2-(thiazol-2-ylamino ethyl1isoindolin-5- yll ethvnvHpyridine-2-carboxylate
  • Step 4 5-G2-G3-Oco-2-G( ⁇ RS)-2-oxo- 1 -rhcnyl-2-tthiazol-2-ylamino)cthyl1isoindolin-5- yl1ethvnyl1-N-(4-piperidv0pyridine-2-carboxamide hydrochloride
  • Step 2 3RSV2.6-Dioxo-3-piperidyll-l.3-dioxo-isoindolin-4-
  • Step 3 N-
  • Step 3 N-rl- -2.6-Dioxo-3-piperidyl1-E3-dioxo-isoindolin-4-yl1amino1butyl1-4-
  • Step 1 tert-Butyl GP RS)-l -t5-fluoro-2-mcthoxynhcnyl)-2-oxo-2-tthiazol-2- ylaminotcthyllcarbamatc
  • Step 2 t2RS)-2-Amino-2-t5-fluoro-2-mcthoxynhcnyl)-N-tthiazol-2-yl)acctamidc hydrochloride
  • Step 3 t2RS)-2-t5-Fluoro-2-mcthoxynhcnyl)-2-t6-iodo- 1 -oxoisoindolin-2-vO-N-(thiazol-2- yl (acetamide
  • Step 4 Methyl 5-G2-G2-GP RS)- 1 -t5-fluoro-2-mcthoxy-phcnyl )-2-oxo-2-(thiazol-2- ylamino)cthyl1-3-oxo-isoindolin-5-yl1cthvnyl1nyridinc-2-carboxylatc
  • Step 5 5-G2-G2-GP RS)- 1 -t5-Fluoro-2-mcthoxy-phcnyl )-2-oxo-2-tthiazol-2-ylamino)cthyl1-3- oxo-isoindolin-5-yl1ethvnyl1PYridine-2-carboxylic acid
  • Step 6 tert-Butyl 4-GG5-G2-G2-GP RS)- 1 -t5-fluoro-2-mcthoxy-phcnyl )-2-oxo-2-tthiazol-2- ylaminoicthyll -3 -oxo-isoindolin-5 -yll ethynyllpyridine -2-carbon yl1 aminolpiperidine- 1 - carboxylate
  • step 1 starting from 5-[2-[(lRS)-l-(5-fluoro-2- methoxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3-oxo-isoindolin-5-yl]ethynyl]-N-(4- piperidyl)pyridine-2-carboxamide hydrochloride (Example 7, step 7) and 4-[[2-[(3RS)-2,6- dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butanoic acid (Example 2, step 5).
  • Step 9 N-G 1 - 3RS)-2,6-Dioxo-3-nineridyl1- l ,3-dioxo-isoindolin-4-yl1amino1butanoyl1-4-
  • BBr3 (1M in dichloromethane) (0.16 ml, 0.16 mmol, 4 equiv.) was added drop wise and the mixture stirred for 1 hour at room temperature. The mixture was cooled to 0-5°C and water (45m1, 2.48 mmol, 60 equiv.) was added drop wise. The mixture was stirred for 10 minutes and evaporated with Isolute ® to dryness. The crude product was purified by flash chromatography on a silica gel column eluting with a methanol: dichloromethane 0: 100 to 20:80 gradient.
  • Step 2 Methyl 3- ⁇ 1iiop>5-G2-G3-oco-2-G( ⁇ RS)-2-oxo- 1 -r>henyl-2-(thiazol-2- ylamino)cthyl1isoindolin-5-yl1cthvnyl1nyridinc-2-carboxylatc
  • Step 4 tert-Butyl 4-GG3-PIIOGO-5-G2-G3-OCO-2-G( ⁇ RS)-2-oxo- 1 -nhenyl-2-(thiazol-2- ylamino)cthyl1isoindolin-5 - yll ethynyllpYridine -2-carbon yl1 aminolpiperidine- 1 -carboxylate
  • Step 1 f2RS)-2-f6-Bromo-l -oxo-isoindolin-2-yl )-2-nhenyl -acetic acid
  • Step 2 f2RS)-2-f6-Bromo-l -oxo-isoindolin-2-yl )-2-nhcnyl-N-f2-nyridyl)acctamidc
  • Step 3 Methyl 5-G2-G3-oco-2-G( ⁇ RS)-2-oxo-l -nhenyl ⁇ - ⁇ -nyridylaminoiethyllisoindolin-S- yll ethvnyllpyridine-2-carboxylate
  • Step 4 5-G2-G3-Oco-2-G( ⁇ RS)-2-oxo- 1 -phcnyl-2-t2-pyridylamino)cthyl1isoindolin-5- yllethvnyllpyridine-2-carboxylic acid
  • step 2 starting from methyl 5-[2-[3-oxo-2-[(lRS)-2-oxo- 1 -phenyl-2-(2-pyridylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2-carboxylate (Example 9, step 3) and tert-butyl 4-aminopiperidine-l-carboxylate.
  • Step 5 tert-Butyl 4- 2-G3-oco-2-G( ⁇ RS)-2-oxo- 1 -phcnyl-2-t2-pyridylamino)cthyl1isoindolin-
  • step 1 starting from 5-[2-[3-oxo-2-[(lRS)-2-oxo-l- phenyl-2-(2-pyridylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2-carboxylic acid (Example 9, step 4) and tert-butyl 4-aminopiperidine-l-carboxylate.
  • Step 6 5-G2-G3-Oco-2-G( ⁇ RS)-2-oxo- 1 -phcnyl-2-t2-pyridylamino)cthyl1isoindolin-5-yl1cthynvn- N-(4-piperidvDpyridine-2-carboxamide
  • Example 11 Example 11
  • Step 1 5-r4-(Bromomcthyl)- 1 -nincridyl1-2-rf3RS)-2.6-dioxo-3-nincridyl]isoindolinc- 1 ,3-dionc
  • Step 1 (2RS)-2-r 1 -Oxo-6-r2-r6-(piperazin- 1 -ylmcthyl )-3-pyridyl1cthvnyl1isoindolin-2-yl1-2- phenyl-N-(2-pyridv0acetamide hydrochloride
  • Step 3 (2RSV2-r6-r2-r6-rr4-r2-rl-r2-r(3RSV2.6-Dioxo-3-piperidyl1-l.3-dioxo-isoindolin-4-yll- 4-piperidyllacetvHpiperazin- 1 -yllmethyll-3-pyridyllethvnyll- 1 -oxo-isoindolin-2-yl1-2-phenyl-N- (2-pyridvOacetamide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Present invention provides compounds that cause specifically the degradation of EGFR via the targeted ubiquitination of EGFR protein and subsequent proteasomal degradation. The present compounds are useful for the treatment of various cancers.

Description

COMPOUNDS WHICH CAUSE DEGRADATION OF EGFR, FOR USE AGAINST CANCER
Field of the Invention
Present invention provides compounds that cause specifically the degradation of EGFR via the targeted ubiquitination of EGFR protein and subsequent proteasomal degradation. The present compounds are useful for the treatment of various cancers.
Background of the Invention
The field of targeted protein degradation promoted by small molecules has been intensively studied over the last years
Protein degradation plays a role in various cellular functions, i.e. the concentrations of regulatory proteins are adjusted through degradation into small peptides to maintain health and productivity of the cells.
Cereblon is a protein that forms an E3 ubiquitin ligase complex, which ubiquinates various other proteins. Cereblon is known as primary target for anticancer thalidomide analogs. A higher expression of cereblon has been linked to the efficiency of thalidomide analogs in cancer therapy.
In the recent years, a few bifunctional compounds have been described as useful modulators of targeted ubiquitination, e.g. WO2013020557 2 , WO2013063560 3 , WO 2013106643 4 , WO2015160845 5 , W020160119066 , W02016105518 7 , W02017007612 8 , WO20170243189 and WO201711747310.
EGFR inhibitors, in particular selective inhibitors of T790M containing EGFR mutants have been described for instance in W0201408171811 , WO201421035412 and Zhou et a/.13
Bifunctional molecules for degradation of EGFR are described for instance in WO201718503614.
However, there is still an ongoing need for effective treatment of cancers.
Summary of the Invention
Present invention provides compounds that cause specifically the degradation of EGFR via the targeted ubiquitination of EGFR protein and subsequent proteasomal degradation. Present compounds are useful for the treatment of various cancers. Present compounds bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) on one hand and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in the recruitment and ubiquitination of EGFR. The present compounds are also selective inhibitors of T790M containing EGFR mutants. Present invention provides compounds of formula I, or a pharmaceutically acceptable salt thereof,
Figure imgf000003_0001
wherein the substituents and variables are as described below and in the claims, or a pharmaceutically acceptable salt thereof
The present compounds are useful for the therapeutic and/or prophylactic treatment of cancer.
The compounds of present invention can further be used as part of bifunctional compounds that comprise the compounds of present invention as E3 Ubiquitin Ligase moiety that is linked to a moiety that binds to a target protein where the target protein is proximate to the ubiquitin ligase to effect degradation of said protein.
Detailed Description of the Invention
The present invention provides a compound of formula I and their pharmaceutically acceptable salts thereof, the preparation of the above mentioned compounds, medicaments containing them and their manufacture as well as the use of the above mentioned compounds in the therapeutic and/or prophylactic treatment of cancer.
The following definitions of the general terms used in the present description apply irrespectively of whether the terms in question appear alone or in combination with other groups.
Unless otherwise stated, the following terms used in this application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms“a”,“an,” and“the” include plural referents unless the context clearly dictates otherwise.
The term "Ci-6-alkyl", alone or in combination with other groups, stands for a hydrocarbon radical which may be linear or branched, with single or multiple branching, wherein the alkyl group in general comprises 1 to 6 carbon atoms, for example, methyl (Me), ethyl (Et), propyl, isopropyl (i-propyl), n-butyl, i-butyl (isobutyl), 2-butyl (sec-butyl), t-butyl (fc/ -butyl), isopentyl, 2-ethyl-propyl (2 -methyl-propyl), 1 ,2-dimethyl-propyl and the like. A specific group is methyl. The term "halogen", alone or in combination with other groups, denotes chloro (Cl), iodo (I), fluoro (F) and bromo (Br). A specific group is F.
The term“hydroxy” means -OH.
The term“heterocyclyl” denotes a monovalent saturated or partly unsaturated mono- or bicyclic ring system of 4 to 9 ring atoms, comprising 1, 2, or 3 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Specific “heterocyclyl” are saturated monocyclic rings systems of 4-6 ring atoms, comprising 1-2 ring heteroatoms that are N. Examples for monocyclic saturated heterocycloalkyl are azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro-thienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, l,l-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl. Examples for bicyclic saturated heterocycloalkyl are 8-aza-bicyclo[3.2.l]octyl, quinuclidinyl, 8-oxa-3-aza-bicyclo[3.2.l]octyl, 9-aza-bicyclo[3.3.l]nonyl, 3-oxa-9-aza- bicyclo[3.3.l]nonyl, or 3-thia-9-aza-bicyclo[3.3.l]nonyl. Examples for partly unsaturated heterocycloalkyl are dihydrofuryl, imidazolinyl, dihydro-oxazolyl, tetrahydro-pyridinyl, or dihydropyranyl. Specific groups are piperazinyl and piperidinyl.
The term“heteroaryl” denotes a monovalent aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms, comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Particular“heteroaryl” have 6 rings atoms, comprising one N. Examples of heteroaryl moieties include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzooxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl. A specific group is pyridinyl.
A“piperazinyl” being part of the subunit“L” is connected at both ends via the respective
“N”.
A“piperidinyl” being part of the subunit“L” is connected at one ends via the“N”.
The subunit“L” is linked via a“C” to the alkynyl moiety of the molecule and with a“N” to the isoindolinyl moiety of the molecule, for example, when L is aryl-(CH2)i_2-heterocyclyl- C(=0)-(CH2)I-IO-NH-, then the compound of formula I is
Figure imgf000005_0001
The term“pharmaceutically acceptable” denotes an attribute of a material which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and is acceptable for veterinary as well as human pharmaceutical use.
The term "a pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and animals. Examples of suitable salts with inorganic and organic acids are, but are not limited to acetic acid, citric acid, formic acid, fumaric acid, hydrochloric acid, lactic acid, maleic acid, malic acid, methane-sulfonic acid, nitric acid, phosphoric acid, p-toluenesulphonic acid, succinic acid, sulfuric acid (sulphuric acid), tartaric acid, trifluoroacetic acid and the like. Particular acids are formic acid, trifluoroacetic acid and hydrochloric acid. A specific acid is trifluoroacetic acid.
The terms“pharmaceutically acceptable auxiliary substance” refer to carriers and auxiliary substances such as diluents or excipients that are compatible with the other ingredients of the formulation.
The term "pharmaceutical composition" encompasses a product comprising specified ingredients in pre-determined amounts or proportions, as well as any product that results, directly or indirectly, from combining specified ingredients in specified amounts. Particularly it encompasses a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product that results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
“Therapeutically effective amount” means an amount of a compound that, when administered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state. The“therapeutically effective amount” will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors. The term“as defined herein” and“as described herein” when referring to a variable incorporates by reference the broad definition of the variable as well as particularly, more particularly and most particularly definitions, if any.
The terms“treating”,“contacting” and“reacting” when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
The term “pharmaceutically acceptable excipient” denotes any ingredient having no therapeutic activity and being non-toxic such as disintegrators, binders, fillers, solvents, buffers, tonicity agents, stabilizers, antioxidants, surfactants or lubricants used in formulating pharmaceutical products. Whenever a chiral carbon is present in a chemical structure, it is intended that all stereoisomers associated with that chiral carbon are encompassed by the structure as pure stereoisomers as well as mixtures thereof.
The invention also provides pharmaceutical compositions, methods of using, and methods of preparing the aforementioned compounds. All separate embodiments may be combined.
El : One embodiment of the invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof,
Figure imgf000006_0001
wherein
L is selected from the group consisting of i) -aryl-(CH2)i-2-heterocyclyl-C(=0)-(CH2)i-io-NH-, in particular a. -phenyl-(CH2)i-2-piperazinyl-C(=0)-(CH2)i-io-NH-;
ii) -heteroaryl-C(=0)-NH-heterocyclyl-C(=0)-(CH2)i_io-NH-, in particular a. -pyridinyl-C(=0)-NH-piperidyl-C(=0)-(CH2)i-io-NH-; iii) -heteroaryl-(CH2)i-2-heterocyclyl-C(=0)-(CH2)i-io-NH-, in particular
a. -pyridinyl-(CH2)i-2-piperazinyl-C(=0)-(CH2)i-io-NH-; iv) -heteroaryl-C(=0)-NH-heterocyclyl-(CH2)i_io-NH-, in particular
a. -pyridinyl-C(=0)-NH-piperidyl-(CH2)i-io-NH-;
v) -heteroaryl-C(=0)-NH-heterocyclyl-(CH2)i_io-heterocyclyl-, in particular a. -pyridinyl-C(=0)-NH-piperidyl-(CH2)i-io-piperidyl-; and
vi) -heteroaryl-(CH2)i-2-heterocyclyl-C(=0)-(CH2)i-io-heterocyclyl-, in particular a. -pyridinyl-(CH2)i-2-piperidyl-C(=0)-(CH2)i-io-piperidyl-, or b. -pyridinyl-(CH2)i-2-piperazinyl-C(=0)-(CH2)i-io-piperidyl-.
whereby each aryl or heteroaryl moiety can be independently substituted by
a. halogen, in particular F, or
b. Ci_6alkyl, in particular methyl;
R1 is H;
A is heteroaryl, in particular
a. thiazolyl, or
b. pyridinyl;
B is aryl, in particular phenyl, which aryl is
a. unsubstituted, or
b. substituted by 1-2 substituents individually selected from
i. halogen, in particular F,
ii. Ci_6alkyl, in particular methyl, and iii. hydroxy.
E2: The compound of formula I, or pharmaceutically acceptable salts thereof, as described herein, wherein L is selected from the group consisting of i) -5F-pyridinyl-C(=0)-NH-piperidyl-(CH2)4-NH-, ii) -phenyl-(CH2) 1 -piperazinyl-C(=0)-(CH2)3-NH-, iii) -phenyl-(CH2) 1 -piperazinyl-C(=0)-(CH2)5-NH-, iv) -pyridinyl-(CH2) 1 -piperazinyl-C(=0)-(CH2)i-piperidyl-, v) -pyridinyl-(CH2) 1 -piperazinyl-C(=0)-(CH2)3-NH-, vi) -pyridinyl-C(=0)-NH-piperidyl-(CH2)i-piperidyl-, vii) -pyridinyl-C(=0)-NH-piperidyl-(CH2)4-NH-, viii) -pyridinyl-C(=0)-NH-piperidyl-C(=0)-(CH2)i-NH-, and ix) -pyridinyl-C(=0)-NH-piperidyl-C(=0)-(CH2)3-NH-.
E3: The compound of formula I, or pharmaceutically acceptable salts thereof, as described herein, wherein A is thiazolyl. E4: The compound of formula I, or pharmaceutically acceptable salts thereof, as described herein, wherein B is phenyl.
E5: The compound of formula I, or pharmaceutically acceptable salts thereof, as described herein, selected from the group consisting of
(2RS)-2-[6-[2-[4-[[4-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4- yl]amino]butanoyl]piperazin-l -yl]methyl]phenyl]ethynyl]-l-oxo-isoindolin-2-yl]-2 -phenyl -N- thiazol-2-yl-acetamide,
(2RS)-2-[6-[2-[4-[[4-[6-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4- yl]amino]hexanoyl]piperazin-l-yl]methyl]phenyl]ethynyl]-l-oxo-isoindolin-2-yl]-2-phenyl-N- thiazol-2-yl-acetamide,
(2RS)-2-[6-[2-[6-[[4-[2-[l-[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]-4- piperidyl] acetyljpiperazin- 1 -yljmethyl] -3 -pyridyl] ethynyl] - 1 -oxo-isoindolin-2-yl] -2 -phenyl -N- (2-pyridyl)acetamide, (2RS)-2-[6-[2-[6-[[4-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4- yl] amino]butanoyl]piperazin- 1 -yljmethyl] -3 -pyridyl] ethynyl] - 1 -oxo-isoindolin-2-yl] -2-phenyl-
N-thiazol-2-yl-acetamide,
N-[l-[[l-[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-5-yl]-4-piperidyl]methyl]-4- piperidyl]-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(2-pyridylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxamide,
N-[l-[2-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]acetyl]-4-piperidyl]-
5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxamide,
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butanoyl]-4- piperidyl]-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxamide,
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butyl]-4-piperidyl]- 5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxamide,
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butanoyl]-4- piperidyl]-5-[2-[2-[(lRS)-l-(5-fluoro-2-hydroxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3- oxo-isoindolin-5-yl]ethynyl]pyridine-2-carboxamide,
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butyl]-4-piperidyl]- 3-fluoro-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxamide,
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butyl]-4-piperidyl]- 5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(2-pyridylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine- 2-carboxamide, and
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butyl]-4-piperidyl]- 5-[2-[2-[(lRS)-l-(5-fluoro-2-hydroxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3-oxo- isoindolin-5-yl]ethynyl]pyridine -2-carboxamide.
1. The compound according to any one of claims 1-5 for use as a medicament.
E6: The compound as described herein, or pharmaceutically acceptable salts thereof, for the therapeutic and/or prophylactic treatment of cancer.
E7: Use of the compound as described herein, or pharmaceutically acceptable salts thereof, for the therapeutic and/or prophylactic treatment of cancer.
E8: A pharmaceutical composition comprising a compound as described herein, and a therapeutically inert carrier. E9: A certain embodiment of the invention refers to the compound of formula I, or pharmaceutically acceptable salts thereof, as described herein, for use as medicament.
E10: A certain embodiment of the invention relates to the compound of formula I as described herein, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.
El l : A certain embodiment of the invention relates to the compound of formula I as described herein, or a pharmaceutically acceptable salt thereof, for the use in the therapeutic and/or prophylactic treatment of cancer.
E12: A certain embodiment of the invention relates to the compound of formula I as described herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of cancer.
E13: A certain embodiment of the invention relates to a pharmaceutical composition comprising the compound of formula I as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary substance.
E14: A certain embodiment of the invention relates to a method for the therapeutic and/or prophylactic treatment of cancer, by administering the compound of formula I as described herein, or a pharmaceutically acceptable salt thereof, to a patient.
Furthermore, the invention includes all optical isomers, i.e. diastereoisomers, diastereomeric mixtures, racemic mixtures, all their corresponding enantiomers and/or tautomers as well as their solvates of the compounds of formula I.
The compounds of formula I may contain one or more asymmetric centers and can therefore occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within this invention. The present invention is meant to encompass all such isomeric forms of these compounds. The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
In the embodiments, where optically pure enantiomers are provided, optically pure enantiomer means that the compound contains > 90 % of the desired isomer by weight, particularly > 95 % of the desired isomer by weight, or more particularly > 99 % of the desired isomer by weight, said weight percent based upon the total weight of the isomer(s) of the compound. Chirally pure or chirally enriched compounds may be prepared by chirally selective synthesis or by separation of enantiomers. The separation of enantiomers may be carried out on the final product or alternatively on a suitable intermediate. The compounds of formula I may be prepared in accordance with the schemes described in the examples. The starting material is commercially available or may be prepared in accordance with known methods.
The preparation of compounds of formula I is further described in more detail in the scheme below.
Scheme 1
Figure imgf000011_0001
An isoindoline-acetylene based compound of general formula I can be obtained for example by amide coupling with an appropriately substituted acid of formula 1 and an appropriately substituted amine of formula 2 with a coupling agent such as TBTU to yield the desired amide derivatives of formula 3. Deprotection followed by ring cyclization with a iodo or bromo substituted methyl 2-(bromomethyl)benzoate of formula 5 yields the desired isoindoline 6. Sonogashira coupling with an appropiate substituted acetlyne of formula 7 forms the desired isoindoline-acetylene based compound of general formula I (scheme 1).
Generally speaking, the sequence of steps used to synthesize the compounds of formula I can also be modified in certain cases. Isolation and purification of the compounds
Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the preparations and examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used. Racemic mixtures of chiral compounds of formula I can be separated using chiral HPLC. Racemic mixtures of chiral synthetic intermediates may also be separated using chiral HPLC.
Salts of compounds of formula
Figure imgf000012_0001
In cases where the compounds of formula I are basic they may be converted to a corresponding acid addition salt. The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained between 0 °C and 50 °C. The resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.
Insofar as their preparation is not described in the examples, the compounds of formula I as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth herein. Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in analogy thereto.
It will be appreciated that the compounds of general formula I in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
Pharmacological Tests
The compounds of formula I and their pharmaceutically acceptable salts possess valuable pharmacological properties. The compounds were investigated in accordance with the test given hereinafter.
EGFR degradation assay (cellular) Generation of BaF3 EGFR mutant cell lines
The BaF3 parental line was purchased from DSMZ and grown in RPMI media
supplemented with 10% FBS and 10 ng/mL interleukin 3 (IL-3) (Thermo Fisher Scientific). EGFR mutants (T790M/L853R, T790M/L853R/C797S) were cloned into the pCDH lentiviral vector (SystemBio) under the control of a PGK promoter and confirmed by DNA sequencing. The resulting gene expression vector for each mutant was mixed with packaging vectors and cotransfected into 2x10E6 HEK293T cells (ATCC) in 10 mL of DMEM media to generate lentiviral particles according to the manufacturers protocol (Origene).
Three days post-transfection, the viral supernatant was harvested and filtered. In one well of a l2-well plate, 0.5 mL of viral supernatant was added to 2E6 Ba/F3 cells contained in 1.5 mL of RPMI media including 10% FBS, 10 ng/mL IL-3, and 5 pg/mL polybrene (Invitrogen). The plate was centrifuged at 2,000 rpm for 1 hour at room temperature and infected cells were kept in a tissue culture incubator overnight at 37°C. The cells were washed once in fresh BaF3 media and reseeded at 0.5E6 cells/well of a l2-well plate in media supplemented with 0.5 pg/mL puromycin. The cells were maintained in this media for 3 weeks. IL-3 -independent, EGFR mutant transformed cells were routinely maintained in RPMI medium supplemented with 10% FBS.
Materials
RPMI 1640 no-phenol red medium and fetal bovine serum (FBS) were purchased from Gibco (Grand Island, NY, USA). EGFR total kit and EGFR phospho-Yl068 kit were purchased from Cisbio (Bedford, MA, USA). BaF3 EGFR mutant cell lines (EGFR T790M/L858R/C797S) cell line was generated in house, according to the protocol reported above. Cell culture flasks and 384-well microplates were acquired from VWR (Radnor, PA , USA).
EGFR degradation analysis
EGFR degradation was determined based on quantification of FRET signal using EGFR total kit. The FRET signal detected correlates with total EGFR protein level in cells. Briefly, test compounds were added to the 384-well plate from a top concentration of 1 pM with 11 points, half log titration in quadruplicates. Then, BaF3 EGFR mutant cell lines (EGFR T790M/L858R/C797S) were added into 384-well plates at a cell density of 10000 cells per well. The plates were kept at 37 °C with 5% C02 for 4 hours. After 4-hour incubation, 4X lysis buffer was added to the cells, and then then microplate was agitated on plate shaker at 500 rpm for 30 minutes at room temperature. Next, total EGFR antibody solution was added to the cells and the cells were incubated for another 4 hours at room temperature. Finally, FRET signal was acquired on EnVision™ Multilabel Reader (PerkinElmer, Santa Clara, CA, USA). The cells treated in the absence of the test compound were the negative control and lysis buffer with antibody solution only were the positive control.
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Pharmaceutical Compositions
The compounds of formula I and the pharmaceutically acceptable salts can be used as therapeutically active substances, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
The compounds of formula I and the pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, com starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatin capsules. Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatin capsules.
Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
The pharmaceutical preparations can, moreover, contain pharmaceutically acceptable auxiliary substances such as preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also provided by the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
The following examples illustrate the present invention without limiting it, but serve merely as representative thereof. The pharmaceutical preparations conveniently contain about 1 - 500 mg, particularly 1-100 mg, of a compound of formula I. Examples of compositions according to the invention are:
Example A
Tablets of the following composition are manufactured in the usual manner:
Figure imgf000017_0001
Table 2: possible tablet composition
Manufacturing Procedure 1. Mix ingredients 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.
3. Pass the granules through suitable milling equipment.
4. Add ingredient 5 and mix for three minutes; compress on a suitable press. Example B-l
Capsules of the following composition are manufactured:
Figure imgf000018_0001
Table 3: possible capsule ingredient composition
Manufacturing Procedure
1. Mix ingredients 1 , 2 and 3 in a suitable mixer for 30 minutes.
2. Add ingredients 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.
The compound of formula I , lactose and com starch are firstly mixed in a mixer and then in a comminuting machine. The mixture is returned to the mixer; the talc is added thereto and mixed thoroughly. The mixture is filled by machine into suitable capsules, e.g. hard gelatin capsules.
Example B-2
Soft Gelatin Capsules of the following composition are manufactured:
Figure imgf000018_0002
Table 4: possible soft gelatin capsule ingredient composition
Figure imgf000019_0001
Table 5: possible soft gelatin capsule composition
Manufacturing Procedure
The compound of formula I is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.
Example C
Suppositories of the following composition are manufactured:
Figure imgf000019_0002
Table 6: possible suppository composition Manufacturing Procedure
The suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45°C. Thereupon, the finely powdered compound of formula I is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size, left to cool; the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.
Example D
Injection solutions of the following composition are manufactured:
Figure imgf000019_0003
Figure imgf000020_0001
Table 7: possible injection solution composition
Manufacturing Procedure
The compound of formula I is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part). The pH is adjusted to 5.0 by acetic acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.
Example E
Sachets of the following composition are manufactured:
Figure imgf000020_0002
Table 8: possible sachet composition Manufacturing Procedure
The compound of formula I is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water. The granulate is mixed with magnesium stearate and the flavoring additives and filled into sachets.
Experimental Part The following examples are provided for illustration of the invention. They should not be considered as limiting the scope of the invention, but merely as being representative thereof.
Example 1
(2RS)-2- [6- [2- [4- [ [4- [6- [ [2- [(3RS)-2,6-Dioxo-3-piperidyl] -1 ,3-dioxo-isoindolin-4- yl] amino] hexanoyl] piperazin- 1-yl] methyl] phenyl] ethynyl] - l-oxo-isoindolin-2-yl] -2-phenyl- N-thiazol-2-yl-acetamide
Step 1 : tert-Butyl N-GP RS)-2-oxo-l -phenyl -2-fthi azol-2-ylam i no )cthyl1carbamatc
Figure imgf000021_0001
(2RS)-2-(tert-Butoxycarbonylamino)-2 -phenyl-acetic acid (9.5 g, 37.8 mmol) was dissolved in 75 ml of ethyl acetate and 10 ml of DMF. Thiazol-2-amine (3.79 g, 37.8 mmol, 1 equiv.), Hunig’s base (14.7 g, 19.8 ml, 113 mmol, 3 equiv.) and Propylphosphonic anhydride solution (50% in ethyl acetate) (36.1 g, 33.8 ml, 56.7 mmol, 1.5 equiv.) were added drop wise at room temperature. The mixture was stirred at room temperature for 30 minutes. The reaction mixture was extracted with saturated NaHCCb-solution and two times with ethyl acetate. The organic layers were extracted with water, dried over sodium sulfate and evaporated to dryness. The desired tert-butyl N-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]carbamate (12 g, 95% yield) was obtained as a light yellow solid, MS: m/e = 334.5 (M+H+).
Step 2: (2RS)-2-Amino-2-phenyl-N-thiazol-2-yl-acetamide hydrochloride
Figure imgf000021_0002
tert-Butyl N-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]carbamate (Example 1, step 1) (12 g, 37 mmol) was dissolved in 100 ml of MeOH and HC1 (4N in dioxane) (27.7 ml, 111 mmol, 3 equiv.) was added at room temperature. The mixture was stirred for 5 hours at room temperature. The reaction mixture was evaporated to dryness and used directly in the next step. The desired (2RS)-2-amino-2-phenyl-N-thiazol-2-yl-acetamide hydrochloride (quantitative yield) was obtained as a grey solid, MS: m/e = 234.4 (M+H+).
Step 3 : (2RS)-2-(6-Iodo- 1 -oxo-isoindolin-2-yl)-2-phenyl-N-thiazol-2-yl-acetamide
Figure imgf000021_0003
(2RS)-2-Amino-2-phenyl-N-thiazol-2-yl-acetamide hydrochloride (Example 1, step 2) (1.22 g, 4.51 mmol) was dissolved in 15 ml of dioxane and 2.5 ml of DMA. Methyl 2-(bromomethyl)-5- iodobenzoate (CAS 1310377-56-0) (1.6 g, 4.51 mmol, 1 equiv.) and triethylamine (2.28 g, 3.14 ml, 22.5 mmol, 5 equiv.) were added at room temperature. The mixture was stirred at l00°C for 2 hours. The reaction mixture was extracted with water and two times with ethyl acetate. The organic layers were extracted with brine, dried over sodium sulfate and evaporated to dryness. The crude product was purified by flash chromatography on a silica gel column eluting with an ethyl acetate :heptane 0: 100 to 100:0 gradient to obtain the desired (2RS)-2-(6-iodo-l-oxo- isoindolin-2-yl)-2-phenyl-N-thiazol-2-yl-acetamide (870 mg, 41 % yield) as a yellow solid, MS: m/e = 475.9 (M+H+).
Step 4: tert-Butyl 4-rf4-cthvnvlphcnvl )mcthyl1pipcraz :- 1 -carboxyl ate
Figure imgf000022_0001
4-Ethynylbenzaldehyde (400 mg, 3.07 mmol) was dissolved in 15 ml of dichloromethane and tert-butyl piperazine- l-carboxylate (690 mg, 3.69 mmol, 1.2 equiv.) followed by sodium triacetoxyhydroborate (780 mg, 3.69 mmol, 1.2 equiv.) were added at room temperature. The mixture was stirred at room temperature for 16 hours. The reaction mixture was extracted with water and two times with dichloromethane. The organic layers were extracted with brine, dried over sodium sulfate and evaporated to dryness. The crude product was purified by flash chromatography on a silica gel column eluting with an ethyl acetate:heptane 0: 100 to 50:50 gradient to obtain the desired tert-butyl 4-(4-ethynylbenzyl)piperazine- l-carboxylate (670 mg, 73 % yield) as a colorless oil, MS: m/e = 301.5 (M+H+).
Step 5 : tert-Butyl 4-IT4-r2-r3-oxo-2-r(TRSV2-oxo-l-phenyl-2-(thiazol-2- ylamino)ethyl1isoindolin-5-yl1ethvnyl1phenyl1methyl1piperazine- l-carboxylate
Figure imgf000022_0002
(2RS)-2-(6-Iodo-l-oxo-isoindolin-2-yl)-2-phenyl-N-thiazol-2-yl-acetamide (Example 1, step 3) (600 mg, 1.26 mmol) and tert-butyl 4-(4-ethynylbenzyl)piperazine- l-carboxylate (Example 1, step 4) (664 mg, 2.21 mmol, 1.75 equiv.) were dissolved in 12 ml of THF. Triethylamine (383 mg, 0.53 ml, 3.79 mmol, 3 equiv.), bis-(triphenylphosphine)-palladium(II)dichloride (87 mg, 0.126 mmol, 0.1 equiv.), triphenylphosphine (66 mg, 0.25 mmol, 0.2 equiv.) and copper(I)iodide (24 mg, 0.126 mmol, 0.1 equiv.) were added and the mixture was stirred for 16 hours at 60°C. The reaction mixture was extracted with water and two times with ethyl acetate. The organic layers were extracted with brine, dried over sodium sulfate and evaporated to dryness. The crude product was purified by flash chromatography on a silica gel column eluting with a dichloromethane:methanol 100:0 to 90:10 gradient. The desired tert-butyl 4-[[4-[2-[3-oxo-2- [(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]phenyl]methyl]piperazine-l-carboxylate (quantitative yield) was obtained as an orange solid, MS: m/e = 646.6 (M+H+).
Step 6: (2RS)-2-f 1 -Qxo-6-r2-r4-fnincrazin- 1 -ylmcthyl )nhcnyl1cthvnyl1isoindolin-2-yl1-2- phenyl-N-thiazol-2-yl-acetamide hydrochloride
Figure imgf000023_0001
The title compound was obtained as a light brown solid, MS: m/e = 546.5 (M+H+), using chemistry similar to that described in Example 1, step 2 starting from tert-butyl 4-[[4-[2-[3-oxo- 2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]phenyl]methyl]piperazine-l-carboxylate (Example 1, step 5).
S 3-pipcridyl1- l .3-dioxo-isoindolin-4-yl1amino1hcxanoic acid
Figure imgf000023_0002
A mixture of 6-aminohexanoic acid (1.7 g, 13.03 mmol, 1.2 equiv.), 2-[(3RS)-2,6-dioxo-3- piperidyl]-4-fluoro-isoindoline-l,3-dione (CAS 835616-60-9) (3 g, 10.86 mmol), Hunig’s base (5.7 ml, 32.58 mmol, 3 equiv.) in 50 ml of DMSO was stirred at 100 °C for 16 hours. Water (500 ml) was added to the reaction mixture and extracted four times with ethyl acetate (200.0 ml each). The combined organic layers were washed with brine, dried over sodium sulfate and concentrated to give a residue. The crude product was purified by flash chromatography on a silica gel column eluting with a petroleum ether:ethyl acetate 3:1 to 0:1 gradient and trituration in dichloromethane to obtain the desired 6-[[2-[(3RS)-2,6-dioxo-3-piperidyl]-l,3-dioxo- isoindolin-4-yl]amino]hexanoic acid (1.4 g, 31 % yield) as a green solid, MS: m/e = 388.1 (M+EE).
Step 8: 3RSV2.6-Dioxo-3-piperidvH-l.3-dioxo-isoindolin-4-
Figure imgf000023_0003
yl1amino1hexanoyl1piperazin-l-yl1methyl1phenyl1ethvnyl1-l-oxo-isoindolin-2-yl1-2-phenyl-N- thiazol-2-yl-acetamide
Figure imgf000024_0001
The title compound was obtained as a yellow solid, MS: m/e = 917.9 (M+H+), using chemistry similar to that described in Example 1, step 1 starting from (2RS)-2-[l-oxo-6-[2-[4-(piperazin-l- ylmethyl)phenyl]ethynyl]isoindolin-2-yl]-2-phenyl-N-thiazol-2-yl-acetamide hydrochloride (Example 1, step 6) and 6-[[2-[(3RS)-2,6-dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4- yl]amino]hexanoic acid (Example 1, step 7).
Example 2
N- [ 1- [4- [ [2- [(3RS)-2,6-Dioxo-3-piperidyl] - 1 ,3-dioxo-isoindolin-4-yl] amino] butanoyl] -4- piperidyl]-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl] ethynyl] pyridine-2-carboxamide
Step 1 : Methyl 5-r2-r3-oxo-2-rnS -2-oxo-l-phenyl-2-(thiazol-2-ylamino ethyl1isoindolin-5- yll ethvnvHpyridine-2-carboxylate
Figure imgf000024_0002
The title compound was obtained as a white solid, MS: m/e = 509.4 (M+H+), using chemistry similar to that described in Example 1, step 5 starting from (2RS)-2-(6-iodo-l-oxo-isoindolin-2- yl)-2-phenyl-N-thiazol-2-yl-acetamide (Example 1, step 3) and methyl 5-ethynylpicolinate.
Step 2: 5-G2-G3-Oco-2-G(Ί RS)-2-oxo- 1 -nhcnyl-2-tthiazol-2-ylamino)cthyl1isoindolin-5- vHethvnyllpyridine-2-carboxylic acid
Figure imgf000024_0003
Methyl 5-[2-[3-oxo-2-[(lS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxylate (Example 2, step 1) (900 mg, 1.77 mmol) was dissolved in 9 ml of THF and 3 ml of MeOH and sodium hydroxide (1M) (3.54 ml, 3.54 mmol, 2 equiv.) was added. The mixture was stirred for 2 hours at room temperature. 5 ml of 1M KHS04 solution were added and the formed precipitate was filtered off, washed with water and dried. The desired 5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxylic acid (862 mg, 99% yield) was obtained as a white solid, MS: m/e = 495.3 (M+H+).
Step 3: tert-Butyl 4-IT5-r2-r3-oxo-2-rnRSy2-oxo-l-phenyl-2-(thiazol-2- ylamino)cthyl1isoindolin-5 - yll ethynyllpyridine -2-carbon yl1 aminolpiperidine- 1 -carboxylate
Figure imgf000025_0001
The title compound was obtained as a light yellow foam, MS: m/e = 677.4 (M+H+), using chemistry similar to that described in Example 1, step 1 starting from 5-[2-[3-oxo-2-[(lRS)-2- oxo- 1 -phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2-carboxylic acid (Example 2, step 2) and tert-butyl 4-aminopiperidine-l -carboxylate.
Step 4: 5-G2-G3-Oco-2-G(Ί RS)-2-oxo- 1 -rhcnyl-2-tthiazol-2-ylamino)cthyl1isoindolin-5- yl1ethvnyl1-N-(4-piperidv0pyridine-2-carboxamide hydrochloride
Figure imgf000025_0002
The title compound was obtained as a light yellow semi-solid, MS: m/e = 577.4 (M+H+), using chemistry similar to that described in Example 1, step 2 starting from tert-butyl 4-[[5-[2-[3-oxo- 2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2- carbonyl]amino]piperidine-l -carboxylate (Example 2, step 3).
S 2.6-Dioxo-3-piperidyl1-E3-dioxo-isoindolin-4-yl1amino1butanoic acid
Figure imgf000025_0003
The title compound was obtained as a lighy green solid, MS: m/e = 360.1 (M+EE), using chemistry similar to that described in Example 1, step 7 starting from 2-[(3RS)-2,6-dioxo-3- piperidyl]-4-fluoro-isoindoline-l,3-dione (CAS 835616-60-9) and 4-aminobutyric acid. Step 6: N-G 1 -G4-GG2-G(3HE)-2,6-Rίoco-3-rίrop n11- 1 ,3-dioxo-isoindolin-4-yl1amino1butanoyl1-4- piperidyl1-5-r2-r3-oxo-2-rnRS -2-oxo-l-phenyl-2-(thiazol-2-ylamino ethyl1isoindolin-5- yl1ethynyl1pyridine-2-carboxamide
Figure imgf000026_0001
The title compound was obtained as a yellow solid, MS: m/e = 918.5 (M+H+), using chemistry similar to that described in Example 1, step 1 starting from 5-[2-[3-oxo-2-[(lRS)-2-oxo-l- phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5-yl]ethynyl]-N-(4-piperidyl)pyridine-2- carboxamide hydrochloride (Example 2, step 4) and 4-[[2-[(3RS)-2,6-dioxo-3-piperidyl]-l,3- dioxo-isoindolin-4-yl]amino]butanoic acid (Example 2, step 5).
Example 3
(2RS)-2- [6- [2- [4- [ [4- [4- [ [2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4- yl]amino]butanoyl]piperazin-l-yl]methyl]phenyl]ethynyl]-l-oxo-isoindolin-2-yl]-2-phenyl-
N-thiazol-2-yl-acetamide
The title compound was obtained as a yellow solid, MS: m/e = 889.5 (M+H+), using chemistry similar to that described in Example 1, step 1 starting from (2RS)-2-[l-oxo-6-[2-[4-(piperazin-l- ylmethyl)phenyl]ethynyl]isoindolin-2-yl]-2-phenyl-N-thiazol-2-yl-acetamide hydrochloride (Example 1, step 6) and 4-[[2-[(3RS)-2,6-dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4- yl]amino]butanoic acid (Example 2, step 5).
Example 4
(2RS)-2- [6- [2- [6- [ [4- [4- [ [2- [(3RS)-2,6-Dioxo-3-piperidyl] -1 ,3-dioxo-isoindolin-4- yl] amino] butanoyl] piperazin-l-yl] methyl] -3-pyridyl] ethynyl] -l-oxo-isoindolin-2-yl] -2- phenyl-N-thiazol-2-yl-acetamide
Step 2: tert-Butyl 4-IY5-ethvnyl-2-pyridv0methvnpiperazine-l-carboxylate e
Figure imgf000026_0002
The title compound was obtained as a brown oil, MS: m/e = 302.2 (M+H+), using chemistry similar to that described in Example 1, step 4 starting from 5-ethynylpicolinaldehyde and tert- butyl piperazine- l-carboxylate.
Step 2: (2RS)-2-f 1 -Oxo-6-r2-r6-(piperazin- 1 -ylmethyl)-3-pyridyl1ethvnyl1isoindolin-2-yl1-2- phenyl-N-thiazol-2-yl-acetamide hydrochloride
Figure imgf000027_0001
The title compound was obtained as an orange solid, MS: m/e = 549.4 (M+H+), using chemistry similar to that described in Example 1, step 5 and 6 starting from (2RS)-2-(6-iodo-l-oxo- isoindolin-2-yl)-2-phenyl-N-thiazol-2-yl-acetamide (Example 1, step 3) and tert-butyl 4-[(5- ethynyl-2-pyridyl)methyl]piperazine- l-carboxylate (Example 4, step 1).
Step 2: 3RSV2.6-Dioxo-3-piperidyll-l.3-dioxo-isoindolin-4-
Figure imgf000027_0002
yl1amino1butanoyl1piperazin-l-yl1methyl1-3-pyridyl1ethvnyl1-l-oxo-isoindolin-2-yl1-2-phenyl-
N-thiazol-2-yl-acetamide
The title compound was obtained as a yellow solid, MS: m/e = 888.6 (M-H+), using chemistry similar to that described in Example 1, step 1 starting from (2RS)-2-[l-oxo-6-[2-[6-(piperazin-l- ylmethyl)-3-pyridyl]ethynyl]isoindolin-2-yl]-2-phenyl-N-thiazol-2-yl-acetamide hydrochloride (Example 4, step 2) and 4-[[2-[(3RS)-2,6-dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4- yl]amino]butanoic acid (Example 2, step 5).
Example 5
N- [ 1- [2- [ [2- [(3RS)-2,6-Dioxo-3-piperidyl] - 1 ,3-dioxo-isoindolin-4-yl] amino] acetyl] -4- piperidyl]-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl] ethynyl] pyridine-2-carboxamide
S t3RS)-2.6-dioxo-3-pincridyl1- 1 ,3-dioxo-isoindolin-4-yl1amino1acetate
Figure imgf000027_0003
The title compound was obtained as a yellow solid, MS: m/e = 332.1 (M+H+-tBu), using chemistry similar to that described in Example 1, step 7 starting from 2-[(3RS)-2,6-dioxo-3- piperidyl]-4-fluoro-isoindoline-l,3-dione (CAS 835616-60-9) and glycine tert-butyl ester hydrochloride.
Step 1 : 2- rt3RS)-2.6-Dioxo-3-pipcridyl1-l .3-dioxo-isoindolin-4-yl1amino1acctic acid
Figure imgf000028_0001
The title compound was obtained as a yellow solid, MS: m/e = 332.1 (M+H+), using chemistry similar to that described in Example 1, step 2 starting from tert-butyl 2-[[2-[(3RS)-2,6-dioxo-3- piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]acetate (Example 5, step 1) by using TFA instead of HC1.
Step 3: N-|TT2-IT2- -2,6-Dioxo-3-piperidvH-l ,3-dioxo-isoindolin-4-vHamino1acetvH-4-
Figure imgf000028_0002
nineridyl1-5-r2-r3-oxo-2-rn RS)-2-oxo- 1 -nhcnyl-2-tthiazol-2-ylamino)cthyl1isoindolin-5- yl1ethvnyl1pyridine-2-carboxamide
Figure imgf000028_0003
The title compound was obtained as an orange semisolid, MS: m/e = 890.5 (M+EE), using chemistry similar to that described in Example 1, step 1 starting from 5-[2-[3-oxo-2-[(lRS)-2- oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5-yl]ethynyl]-N-(4-piperidyl)pyridine-2- carboxamide hydrochloride (Example 2, step 4) and 2-[[2-[(3RS)-2,6-dioxo-3-piperidyl]-l,3- dioxo-isoindolin-4-yl] amino] acetic acid (Example 5, step 2).
Example 6
N- [ 1- [4- [ [2- [(3RS)-2,6-Dioxo-3-piperidyl] - 1 ,3-dioxo-isoindolin-4-yl] amino] butyl] -4- piperidyl]-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl] ethynyl] pyridine-2-carboxamide
Step 1 : 2-rt3RS)-2.6-Dioxo-3-pipcridyl1-4-t4-hvdroxybutylamino)isoindolinc- 1 ,3-dione
Figure imgf000029_0001
The title compound was obtained as an orange oil, MS: m/e = 346.2 (M+H+), using chemistry similar to that described in Example 1, step 7 starting from 2-[(3RS)-2,6-dioxo-3-piperidyl]-4- fluoro-isoindoline-l,3-dione (CAS 835616-60-9) and 4-aminobutan-l-ol by using NMP instead of DMSO as solvent.
Step 2: 4-t4-Bromobutylamino)-2-rt3RS)-2.6-dioxo-3-pipcridyl1isoindolinc-l .3-dionc
Figure imgf000029_0002
A mixture of 2-[(3RS)-2,6-dioxo-3-piperidyl]-4-(4-hydroxybutylamino)isoindoline-l,3-dione (Example 6, step 1) (1 g, 2.9 mmol), triphenylphosphine (910 mg, 3.47 mmol, 1.2 equiv.) and carbon tetrabromide (1.15 g, 3.47 mmol, 1.2 equiv.) in DCM (30 ml) was stirred at room temperature for 2 hours. The mixture was evaporated and the crude product was purified by flash chromatography on a silica gel column eluting with a heptane:ethyl acetate 100:0 to 50:50 gradient to obtain the desired 4-(4-bromobutylamino)-2-[(3RS)-2,6-dioxo-3- piperidyl]isoindoline-l,3-dione (860 mg, 68 % yield) as dark green foam, MS: m/e = 410.2/412.2 (M+H+).
Step 3: N-rl- -2.6-Dioxo-3-piperidyl1-E3-dioxo-isoindolin-4-yl1amino1butyl1-4-
Figure imgf000029_0003
nineridyl1-5-r2-r3-oxo-2-rn RS)-2-oxo- 1 -nhcnyl-2-fthiazol-2-ylamino)cthyl1isoindolin-5- vHethvnvHpyridine-2-carboxamide
Figure imgf000029_0004
5-[2-[3-Oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5-yl]ethynyl]-N-(4- piperidyl)pyridine-2-carboxamide hydrochloride (Example 2, step 4) (65 mg, 0.106 mmol) was dissolved in 5 ml of DMF. 4-(4-Bromobutylamino)-2-[(3RS)-2,6-dioxo-3-piperidyl]isoindoline- l,3-dione (Example 6, step 2) (52 mg, 0.127 mmol, 1.2 equiv.) and Hunig’s base (82 mg, 0.636 mmol, 6 equiv.) were added at room temperature. The mixture was stirred at 60°C for 48 hours. The reaction mixture was extracted with water and several times with dichlormethane:methanol 9:1 mixture. The organic layers were dried over sodium sulfate and evaporated to dryness. The crude product was purified by flash chromatography on a silica gel column eluting with a dichloromethane:methanol 100:0 to 90:10 gradient to obtain the desired N-[l-[4-[[2-[(3RS)-2,6- dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butyl]-4-piperidyl]-5-[2-[3-oxo-2-[(lRS)-2- oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2-carboxamide (12 mg, 13 % yield) as a yellow semisolid, MS: m/e = 904.5 (M+H+).
Example 7
N- [ 1- [4- [ [2- [(3RS)-2,6-Dioxo-3-piperidyl] - 1 ,3-dioxo-isoindolin-4-yl] amino] butanoyl] -4- piperidyl]-5-[2-[2-[(lRS)-l-(5-fluoro-2-hydroxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]- 3-oxo-isoindolin-5-yl] ethynyl] pyridine-2-carboxamide
Step 1 : tert-Butyl GP RS)-l -t5-fluoro-2-mcthoxynhcnyl)-2-oxo-2-tthiazol-2- ylaminotcthyllcarbamatc
The title compound was obtained as a white solid, MS: m/e = 382.5 (M+H+), using chemistry similar to that described in Example 1, step 1 starting from (2RS)-2-((tert- butoxycarbonyl)amino)-2-(5-fluoro-2-methoxyphenyl)acetic acid.
Step 2: t2RS)-2-Amino-2-t5-fluoro-2-mcthoxynhcnyl)-N-tthiazol-2-yl)acctamidc hydrochloride
The title compound was obtained as a light green solid, MS: m/e = 282.4 (M+H+), using chemistry similar to that described in Example 1, step 2 starting from tert-butyl [(lRS)-l-(5- fluoro-2-methoxyphenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]carbamate (Example 7, step 1).
Step 3 : t2RS)-2-t5-Fluoro-2-mcthoxynhcnyl)-2-t6-iodo- 1 -oxoisoindolin-2-vO-N-(thiazol-2- yl (acetamide
The title compound was obtained as a white solid, MS: m/e = 524.4 (M+EE), using chemistry similar to that described in Example 1, step 3 starting from (2RS)-2-amino-2-(5-fluoro-2- methoxyphenyl)-N-(thiazol-2-yl)acetamide hydrochloride (Example 7, step 2) and methyl 2- (bromomethyl)-5-iodobenzoate.
Step 4: Methyl 5-G2-G2-GP RS)- 1 -t5-fluoro-2-mcthoxy-phcnyl )-2-oxo-2-(thiazol-2- ylamino)cthyl1-3-oxo-isoindolin-5-yl1cthvnyl1nyridinc-2-carboxylatc
Figure imgf000030_0001
The title compound was obtained as a yellow solid, MS: m/e = 557.3 (M+EE), using chemistry similar to that described in Example 1, step 5 starting from (2RS)-2-(5-fluoro-2- methoxyphenyl)-2-(6-iodo-l-oxoisoindolin-2-yl)-N-(thiazol-2-yl)acetamide (Example 7, step 3) and methyl 5-ethynylpicolinate. Step 5: 5-G2-G2-GP RS)- 1 -t5-Fluoro-2-mcthoxy-phcnyl )-2-oxo-2-tthiazol-2-ylamino)cthyl1-3- oxo-isoindolin-5-yl1ethvnyl1PYridine-2-carboxylic acid
Figure imgf000031_0001
The title compound was obtained as a yellow solid, MS: m/e = 543.3 (M+EE), using chemistry similar to that described in Example 2, step 2 starting from methyl 5-[2-[2-[(lRS)-l-(5-fluoro-2- methoxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3-oxo-isoindolin-5-yl]ethynyl]pyridine-2- carboxylate (Example 7, step 4) and tert-butyl 4-aminopiperidine-l-carboxylate.
Step 6: tert-Butyl 4-GG5-G2-G2-GP RS)- 1 -t5-fluoro-2-mcthoxy-phcnyl )-2-oxo-2-tthiazol-2- ylaminoicthyll -3 -oxo-isoindolin-5 -yll ethynyllpyridine -2-carbon yl1 aminolpiperidine- 1 - carboxylate
Figure imgf000031_0002
The title compound was obtained as a light yellow solid, MS: m/e = 725.5 (M+H+), using chemistry similar to that described in Example 1, step 1 starting from 5-[2-[2-[(lRS)-l-(5-fluoro-
2-methoxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3-oxo-isoindolin-5-yl]ethynyl]pyridine-2- carboxylic acid (Example 7, step 5) and tert-butyl 4-aminopiperidine-l-carboxylate.
Step 7: 5-G2-G2-GP RS)- 1 -t5-Fluoro-2-mcthoxy-phcnyl )-2-oxo-2-tthiazol-2-ylamino)cthyl1-3- oxo-isoindolin-5-yl1ethvnvf|-N-(4-piperidv0pyridine-2-carboxamide hydrochloride
Figure imgf000031_0003
The title compound was obtained as a yellow solid, MS: m/e = 625.4 (M+H+), using chemistry similar to that described in Example 1, step 2 starting from tert-butyl 4-[[5-[2-[2-[(lRS)-l-(5- fluoro-2-methoxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3-oxo-isoindolin-5- yl]ethynyl]pyridine-2-carbonyl]amino]piperidine-l -carboxyl ate (Example 7, step 6). Step 8: N-G 1 - 1 ,3-dioxo-isoindolin-4-yl1amino1butanoyl1-4-
Figure imgf000032_0001
piperidyl1-5-r2-r2-r -l-(5-fluoro-2-methoxy-phenvn-2-oxo-2-(thiazol-2-ylamino ethyl1-3-
Figure imgf000032_0002
oxo-isoindolin-5-yl1ethvnyl1PYridine-2-carboxamide
Figure imgf000032_0003
The title compound was obtained as a yellow solid, MS: m/e = 966.7 (M+H+), using chemistry similar to that described in Example 1, step 1 starting from 5-[2-[2-[(lRS)-l-(5-fluoro-2- methoxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3-oxo-isoindolin-5-yl]ethynyl]-N-(4- piperidyl)pyridine-2-carboxamide hydrochloride (Example 7, step 7) and 4-[[2-[(3RS)-2,6- dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butanoic acid (Example 2, step 5).
Step 9: N-G 1 - 3RS)-2,6-Dioxo-3-nineridyl1- l ,3-dioxo-isoindolin-4-yl1amino1butanoyl1-4-
Figure imgf000032_0004
piperidyl1-5-r2-r2-r( l RS)- 1 -('5-fluoro-2-hvdroxy-phcnyl )-2-oxo-2-('thiazol-2-ylamino)cthyl1-3- oxo-isoindolin-5-yl1ethvnyl1pyridine-2-carboxamide
Figure imgf000032_0005
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butanoyl]-4- piperidyl]-5-[2-[2-[(lRS)-l-(5-fluoro-2-methoxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3- oxo-isoindolin-5-yl]ethynyl]pyridine-2-carboxamide (Example 7, step 8) (40 mg, 0.041 mmol) was dissolved in 1 ml of dichloromethane and cooled to 0-5°C. BBr3 (1M in dichloromethane) (0.16 ml, 0.16 mmol, 4 equiv.) was added drop wise and the mixture stirred for 1 hour at room temperature. The mixture was cooled to 0-5°C and water (45m1, 2.48 mmol, 60 equiv.) was added drop wise. The mixture was stirred for 10 minutes and evaporated with Isolute® to dryness. The crude product was purified by flash chromatography on a silica gel column eluting with a methanol: dichloromethane 0: 100 to 20:80 gradient. The desired N-[l-[4-[[2-[(3RS)-2,6- dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butanoyl]-4-piperidyl]-5-[2-[2-[(lRS)-l-(5- fluoro-2-hydroxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3-oxo-isoindolin-5- yl]ethynyl]pyridine-2-carboxamide (22 mg, 55 % yield) was obtained as a yellow solid, MS: m/e = 952.8 (M+H+).
Example 8
N- [ 1- [4- [ [2- [(3RS)-2,6-Dioxo-3-piperidyl] - 1 ,3-dioxo-isoindolin-4-yl] amino] butyl] -4- piperidyl]-3-fluoro-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2- ylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2-carboxamide
Step 1 : (2RS)-2-r 1 -Qxo-6-t2-trimcthylsilylcthvnyl)isoindolin-2-yl1-2-phcnyl-N-thiazol-2-yl- acetamide
Figure imgf000033_0001
The title compound was obtained as a light yellow foam, MS: m/e = 446.3 (M+H+), using chemistry similar to that described in Example 1, step 5 starting from (2RS)-2-(6-iodo-l-oxo- isoindolin-2-yl)-2-phenyl-N-thiazol-2-yl-acetamide (Example 1, step 3) and ethynyltrimethylsilane .
Step 2: Methyl 3-ί1iiop>5-G2-G3-oco-2-G(Ί RS)-2-oxo- 1 -r>henyl-2-(thiazol-2- ylamino)cthyl1isoindolin-5-yl1cthvnyl1nyridinc-2-carboxylatc
Figure imgf000033_0002
The title compound was obtained as a yellow solid, MS: m/e = 527.3 (M+H+), using chemistry similar to that described in Example 1, step 5 starting from (2RS)-2-[l-oxo-6-(2- trimethylsilylethynyl)isoindolin-2-yl]-2-phenyl-N-thiazol-2-yl-acetamide (Example 8, step 1) and methyl 5-bromo-3-fluoropicolinate by using TBAF for the cleavage of the trimethylsilyl protecting group.
Step 3 : 3- 5-G2-G3-OCO-2-G(Ί RS)-2-oxo- 1 -rhcnyl-2-tthiazol-2-ylamino)cthyl1isoindolin-5-
Figure imgf000033_0003
yllethvnyllpyridine-2-carboxylic acid
Figure imgf000034_0001
The title compound was obtained as a yellow solid, MS: m/e = 513.3 (M+H+), using chemistry similar to that described in Example 2, step 2 starting from methyl 3-fluoro-5-[2-[3-oxo-2- [(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2- carboxylate (Example 8, step 2).
Step 4: tert-Butyl 4-GG3-PIIOGO-5-G2-G3-OCO-2-G(Ί RS)-2-oxo- 1 -nhenyl-2-(thiazol-2- ylamino)cthyl1isoindolin-5 - yll ethynyllpYridine -2-carbon yl1 aminolpiperidine- 1 -carboxylate
Figure imgf000034_0002
The title compound was obtained as an orange foam, MS: m/e = 695.6 (M+H+), using chemistry similar to that described in Example 1, step 1 starting from 3-fluoro-5-[2-[3-oxo-2-[(lRS)-2-oxo- l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2-carboxylic acid
(Example 8, step 3) and tert-butyl 4-aminopiperidine-l -carboxylate.
Step 4: 3- 5-G2-G3-OCO-2-G(Ί RS)-2-oxo- 1 -nhcnyl-2-tthiazol-2-ylamino)cthyl1isoindolin-5-
Figure imgf000034_0003
yl1ethvnyl1-N-(4-piperidv0pyridine-2-carboxamide hydrochloride
Figure imgf000034_0004
The title compound was obtained as a yellow solid, MS: m/e = 595.4 (M+EE), using chemistry similar to that described in Example 1, step 2 starting from tert-butyl 4-[[3-fluoro-5-[2-[3-oxo-2- [(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2- carbonyl]amino]piperidine-l -carboxylate (Example 8, step 4).
Step 5: N-G 1 -r4- rt3RS)-2.6-Dioxo-3-nincridyl1-1.3-dioxo-isoindolin-4-yl1amino1butyl1-4-
Figure imgf000034_0005
piperidyl1-3-fluoro-5-r2-r3-oxo-2-r -2-oxo-l-phenyl-2-(thiazol-2-ylamino ethyl1isoindolin-
Figure imgf000034_0006
5 -yll ethvnyllpyridine-2-carboxamide
Figure imgf000035_0001
The title compound was obtained as a yellow solid, MS: m/e = 922.5 (M+H+), using chemistry similar to that described in Example 6, step 3 starting from 3-fluoro-5-[2-[3-oxo-2-[(lRS)-2-oxo- l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5-yl]ethynyl]-N-(4-piperidyl)pyridine-2- carboxamide hydrochloride (Example 8, step 4) and 4-(4-bromobutylamino)-2-[(3RS)-2,6-dioxo- 3-piperidyl]isoindoline-l,3-dione (Example 6, step 2).
Example 9
N- [ 1- [4- [ [2- [(3RS)-2,6-Dioxo-3-piperidyl] - 1 ,3-dioxo-isoindolin-4-yl] amino] butyl] -4- piperidyl]-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(2-pyridylamino)ethyl]isoindolin-5- yl] ethynyl] pyridine-2-carboxamide
Step 1 : f2RS)-2-f6-Bromo-l -oxo-isoindolin-2-yl )-2-nhenyl -acetic acid
6-Bromoisoindolin-l-one (4 g, 18.9 mmol) was suspended in 70 ml of THF and cooled to 0-5°C. Sodium hydride (60% in mineral oil) (1.5 g, 37.7 mmol, 2 equiv.) was added in portions at 0-5°C and after 5 minutes (2RS)-2-bromo-2-phenyl-acetic acid (4.34 g, 20.2 mmol, 1.07 equiv.) were added and the mixture was stirred at 0-5° C for 2 hours. The reaction mixture was extracted with 1M HC1 solution and twice with ethyl acetate. The organic layers were dried over sodium sulfate and evaporated to dryness to obtain the desired (2RS)-2-(6-bromo-l-oxo-isoindolin-2-yl)-2- phenyl-acetic acid (5.78 g, 89 % yield) as a white solid, MS: m/e = 345.9/347.9 (M+H+).
Step 2: f2RS)-2-f6-Bromo-l -oxo-isoindolin-2-yl )-2-nhcnyl-N-f2-nyridyl)acctamidc
The title compound was obtained as a lighy yellow solid, MS: m/e = 421.9/423.9 (M+H+), using chemistry similar to that described in Example 1, step 1 starting from (2RS)-2-(6-bromo-l-oxo- isoindolin-2-yl)-2-phenyl-acetic acid (Example 9, step 1) and 2-aminopyridine.
Step 3: Methyl 5-G2-G3-oco-2-G(Ί RS)-2-oxo-l -nhenyl^-^-nyridylaminoiethyllisoindolin-S- yll ethvnyllpyridine-2-carboxylate
Figure imgf000035_0002
The title compound was obtained as a yellow solid, MS: m/e = 503.4 (M+H+), using chemistry similar to that described in Example 1 , step 5 starting from (2RS)-2-(6-bromo-l-oxo-isoindolin-
2-yl)-2-phenyl-N-(2-pyridyl)acetamid (Example 9, step 2) and methyl 5-ethynylpicolinate.
Step 4: 5-G2-G3-Oco-2-G(Ί RS)-2-oxo- 1 -phcnyl-2-t2-pyridylamino)cthyl1isoindolin-5- yllethvnyllpyridine-2-carboxylic acid
Figure imgf000036_0001
The title compound was obtained as a white solid, MS: m/e = 489.4 (M+EE), using chemistry similar to that described in Example 2, step 2 starting from methyl 5-[2-[3-oxo-2-[(lRS)-2-oxo- 1 -phenyl-2-(2-pyridylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2-carboxylate (Example 9, step 3) and tert-butyl 4-aminopiperidine-l-carboxylate.
Step 5: tert-Butyl 4- 2-G3-oco-2-G(Ί RS)-2-oxo- 1 -phcnyl-2-t2-pyridylamino)cthyl1isoindolin-
Figure imgf000036_0002
5-yl1ethvnyl1pyridine-2-carbonyl1amino1piperidine- 1 -carboxylate
Figure imgf000036_0003
The title compound was obtained as a white foam, MS: m/e = 671.6 (M+EE), using chemistry similar to that described in Example 1, step 1 starting from 5-[2-[3-oxo-2-[(lRS)-2-oxo-l- phenyl-2-(2-pyridylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2-carboxylic acid (Example 9, step 4) and tert-butyl 4-aminopiperidine-l-carboxylate.
Step 6: 5-G2-G3-Oco-2-G(Ί RS)-2-oxo- 1 -phcnyl-2-t2-pyridylamino)cthyl1isoindolin-5-yl1cthynvn- N-(4-piperidvDpyridine-2-carboxamide
Figure imgf000036_0004
The title compound was obtained as a white solid, MS: m/e = 571.5 (M+H+), using chemistry similar to that described in Example 1, step 2 starting from tert-butyl 4-[[5-[2-[3-oxo-2-[(lRS)-2- oxo-l-phenyl-2-(2-pyridylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine-2- carbonyl] amino]piperidine-l-carboxylate (Example 9, step 5).
Step 7: N-rl-r4- -2.6-Dioxo-3-piperidyl1-l.3-dioxo-isoindolin-4-yl]amino1butyl1-4-
Figure imgf000037_0001
rΐrop nP-5-G2-G3-oco-2-G(Ί RS)-2-oxo- 1 -phcnyl-2-t2-pyridylamino)cthyl1isoindolin-5- yllethvnyllpyridine-2-carboxamide
Figure imgf000037_0002
The title compound was obtained as a yellow foam, MS: m/e = 899.0 (M+H+), using chemistry similar to that described in Example 6, step 3 starting from 5-[2-[3-oxo-2-[(lRS)-2-oxo-l- phenyl-2-(2-pyridylamino)ethyl]isoindolin-5-yl]ethynyl]-N-(4-piperidyl)pyridine-2-carboxamide (Example 9, step 6) and 4-(4-bromobutylamino)-2-[(3RS)-2,6-dioxo-3-piperidyl]isoindoline-l,3- dione (Example 6, step 2).
Example 10
N- [ 1- [4- [ [2- [(3RS)-2,6-Dioxo-3-piperidyl] - 1 ,3-dioxo-isoindolin-4-yl] amino] butyl] -4- piperidyl]-5-[2-[2-[(lRS)-l-(5-fluoro-2-hydroxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]- 3-oxo-isoindolin-5-yl] ethynyl] pyridine-2-carboxamide
The title compound was obtained as a yellow solid, MS: m/e = 938.9 (M+EE), using chemistry similar to that described in Example 6, step 3 and Example 7, step 9 starting from 5-[2-[2- [(lRS)-l-(5-fluoro-2-methoxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3-oxo-isoindolin-5- yl]ethynyl]-N-(4-piperidyl)pyridine-2-carboxamide hydrochloride (Example 7, step 7) and 4-(4- bromobutylamino)-2-[(3RS)-2,6-dioxo-3-piperidyl]isoindoline-l,3-dione (Example 6, step 2). Example 11
N- [ 1- [ [ 1- [2- [(3RS)-2,6-Dioxo-3-piperidyl] - 1 ,3-dioxo-isoindolin-5-yl] -4-piperidyl] methyl] -4- piperidyl]-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(2-pyridylamino)ethyl]isoindolin-5- yl] ethynyl] pyridine-2-carboxamide
Step 1 : 5-r4-(Bromomcthyl)- 1 -nincridyl1-2-rf3RS)-2.6-dioxo-3-nincridyl]isoindolinc- 1 ,3-dionc
Figure imgf000037_0003
The title compound was obtained as a yellow solid, MS: m/e = 434.0/436.0 (M+H+), using chemistry similar to that described in Example 6, step 1 and step 2 starting from 2-[(3RS)-2,6- dioxo-3-piperidyl]-5-fluoro-isoindoline-l,3-dione (CAS 835616-61-0) and 4-piperidylmethanol. Step 2: N-rl- -2.6-Dioxo-3-piperidyl1-l.3-dioxo-isoindolin-5-yl1-4-
Figure imgf000038_0001
piperidyl1methyl1-4-piperidyl1-5-r2-r3-oxo-2- -2-oxo-l-phenyl-2-(2-
Figure imgf000038_0002
nyridylamino)cthyl1isoindolin-5-yl1cthvnyl1nyridinc-2-carboxamidc
Figure imgf000038_0003
The title compound was obtained as a yellow solid, MS: m/e = 925.7 (M+H+), using chemistry similar to that described in Example 6, step 3 starting from 5-[2-[3-oxo-2-[(lRS)-2-oxo-l- phenyl-2-(2-pyridylamino)ethyl]isoindolin-5-yl]ethynyl]-N-(4-piperidyl)pyridine-2-carboxamide (Example 9, step 6) and 5-[4-(bromomethyl)-l-piperidyl]-2-[(3RS)-2,6-dioxo-3- piperidyl]isoindoline-l,3-dione (Example 11, step 1).
Example 12
(2RS)-2- [6- [2- [6- [ [4- [2- [ 1- [2- [(3RS)-2,6-Dioxo-3-piperidyl] -1 ,3-dioxo-isoindolin-4-yl] -4- piperidyl]acetyl]piperazin-l-yl]methyl]-3-pyridyl]ethynyl]-l-oxo-isoindolin-2-yl]-2-phenyl-
N-(2-pyridyl)acetamide
Step 1 : (2RS)-2-r 1 -Oxo-6-r2-r6-(piperazin- 1 -ylmcthyl )-3-pyridyl1cthvnyl1isoindolin-2-yl1-2- phenyl-N-(2-pyridv0acetamide hydrochloride
Figure imgf000038_0004
The title compound was obtained as a yellow solid, MS: m/e = 543.4 (M+H+), using chemistry similar to that described in Example 1, step 5 and step 6 starting from (2RS)-2-(6-bromo-l-oxo- isoindolin-2-yl)-2-phenyl-N-(2-pyridyl)acetamid (Example 9, step 2) and tert-butyl 4-[(5- ethynyl-2-pyridyl)methyl]piperazine-l-carboxylate (Example 4, step 1).
Step 2: 2-G 1 -r2-r(3RS)-2,6-Dioxo-3-nineridyl1- 1 ,3-dioxo-isoindolin-4-yl1-4-nincridyl1acetic acid
Figure imgf000038_0005
The title compound was obtained as a yellow solid, MS: m/e = 400.1 (M+H+), using chemistry similar to that described in Example 1, step 7 starting from 2-[(3RS)-2,6-dioxo-3-piperidyl]-4- fluoro-isoindoline-l,3-dione (CAS 835616-60-9) and 2-(4-piperidyl)acetic acid hydrochloride. Step 3: (2RSV2-r6-r2-r6-rr4-r2-rl-r2-r(3RSV2.6-Dioxo-3-piperidyl1-l.3-dioxo-isoindolin-4-yll- 4-piperidyllacetvHpiperazin- 1 -yllmethyll-3-pyridyllethvnyll- 1 -oxo-isoindolin-2-yl1-2-phenyl-N- (2-pyridvOacetamide
Figure imgf000039_0001
The title compound was obtained as a yellow solid, MS: m/e = 924.6 (M-H+), using chemistry similar to that described in Example 1, step 1 starting from (2RS)-2-[l-oxo-6-[2-[6-(piperazin-l- ylmethyl)-3-pyridyl]ethynyl]isoindolin-2-yl]-2-phenyl-N-(2-pyridyl)acetamide hydrochloride (example 12, step 1) and 2-[l-[2-[(3RS)-2,6-dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]-4- piperidyl] acetic acid (Example 12, step 2).
1 Collins et al., Biochem J, 2017, 474(7), 1127-47
2 W02013020557
3 W02013063560
4 WO 2013106643
5 WO2015160845
6 W02016011906
7 W02016105518
8 W02017007612
9 WO2017024318
10 WO2017117473
11 W02014081718
12 WO2014210354
13 ZHOU et al., "Novel mutant-selective EGFR kinase inhibitors against EGFR T790M", NATURE, (20091224), vol. 462, no. 7276, doi:l0T038/nature08622, ISSN 0028-0836, pages 1070 - 1074
14 WO2017185036

Claims

Claims
1. A compound of formula I, or a pharmaceutically acceptable salt thereof,
Figure imgf000040_0001
wherein
L is selected from the group consisting of
i) -aryl-(CH2)i-2-heterocyclyl-C(=0)-(CH2)i-io-NH-, in particular
a. -phenyl-(CH2)i-2-piperazinyl-C(=0)-(CH2)i-io-NH-;
ii) -heteroaryl-C(=0)-NH-heterocyclyl-C(=0)-(CH2)i_io-NH-, in particular a. -pyridinyl-C(=0)-NH-piperidyl-C(=0)-(CH2)i-io-NH-; iii) -heteroaryl-(CH2)i-2-heterocyclyl-C(=0)-(CH2)i-io-NH-, in particular
a. -pyridinyl-(CH2)i-2-piperazinyl-C(=0)-(CH2)i-io-NH-; iv) -heteroaryl-C(=0)-NH-heterocyclyl-(CH2)i_io-NH-, in particular
a. -pyridinyl-C(=0)-NH-piperidyl-(CH2)i-io-NH-;
v) -heteroaryl-C(=0)-NH-heterocyclyl-(CH2)i_io-heterocyclyl-, in particular a. -pyridinyl-C(=0)-NH-piperidyl-(CH2)i-io-piperidyl-; and
vi) -heteroaryl-(CH2)i-2-heterocyclyl-C(=0)-(CH2)i-io-heterocyclyl-, in particular a. -pyridinyl-(CH2)i-2-piperidyl-C(=0)-(CH2)i-io-piperidyl-, or b. -pyridinyl-(CH2)i-2-piperazinyl-C(=0)-(CH2)i-io-piperidyl-.
whereby each aryl or heteroaryl moiety can be independently substituted by
a. halogen, in particular F, or b. Ci_6alkyl, in particular methyl;
R1 is H;
A is heteroaryl, in particular a. thiazolyl, or b. pyridinyl;
B is aryl, in particular phenyl, which aryl is a. unsubstituted, or b. substituted by 1-2 substituents individually selected from i. halogen, in particular F, ii. Ci_6alkyl, in particular methyl, and iii. hydroxy.
2. The compound of formula I, or pharmaceutically acceptable salts thereof, according to claim 1 , wherein L is selected from the group consisting of i) -5F-pyridinyl-C(=0)-NH-piperidyl-(CH2)4-NH-, ϋ) -phenyl-(CH2) 1 -piperazinyl-C(=0)-(CH2)3-NH-, iii) -phenyl-(CH2) 1 -piperazinyl-C(=0)-(CH2)5-NH-, iv) -pyridinyl-(CH2) 1 -piperazinyl-C(=0)-(CH2)i-piperidyl-, v) -pyridinyl-(CH2) 1 -piperazinyl-C(=0)-(CH2)3-NH-, vi) -pyridinyl-C(=0)-NH-piperidyl-(CH2)i-piperidyl- vii) -pyridinyl-C(=0)-NH-piperidyl-(CH2)4-NH- viii) -pyridinyl-C(=0)-NH-piperidyl-C(=0)-(CH2)i-NH-, and ix) -pyridinyl-C(=0)-NH-piperidyl-C(=0)-(CH2)3-NH-.
3. The compound of formula I, or pharmaceutically acceptable salts thereof, according to any one of claims 1-2, wherein A is thiazolyl.
4. The compound of formula I, or pharmaceutically acceptable salts thereof, according to any one of claims 1-3, wherein B is phenyl.
5. The compound of formula I, or pharmaceutically acceptable salts thereof, according to any one of claims 1-4, selected from the group consisting of (2RS)-2-[6-[2-[4-[[4-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4- yl] amino]butanoyl]piperazin- 1 -yl]methyl]phenyl] ethynyl] - 1 -oxo-isoindolin-2-yl] -2 -phenyl -N- thiazol-2-yl-acetamide,
(2RS)-2-[6-[2-[4-[[4-[6-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4- yl]amino]hexanoyl]piperazin-l-yl]methyl]phenyl]ethynyl]-l-oxo-isoindolin-2-yl]-2-phenyl-N- thiazol-2-yl-acetamide,
(2RS)-2-[6-[2-[6-[[4-[2-[l-[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]-4- piperidyl] acetyljpiperazin- 1 -yljmethyl] -3 -pyridyl] ethynyl] - 1 -oxo-isoindolin-2-yl] -2 -phenyl -N- (2-pyridyl)acetamide,
(2RS)-2-[6-[2-[6-[[4-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4- yl]amino]butanoyl]piperazin-l -yljmethyl] -3 -pyridyl] ethynyl] -l-oxo-isoindolin-2-yl] -2 -phenyl-
N-thiazol-2-yl-acetamide,
N-[l-[[l-[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-5-yl]-4-piperidyl]methyl]-4- piperidyl]-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(2-pyridylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxamide,
N-[l-[2-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]acetyl]-4-piperidyl]- 5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxamide,
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butanoyl]-4- piperidyl]-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxamide,
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butyl]-4-piperidyl]-
5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxamide,
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butanoyl]-4- piperidyl]-5-[2-[2-[(lRS)-l-(5-fluoro-2-hydroxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3- oxo-isoindolin-5-yl]ethynyl]pyridine-2-carboxamide,
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butyl]-4-piperidyl]-
3-fluoro-5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(thiazol-2-ylamino)ethyl]isoindolin-5- yl]ethynyl]pyridine-2-carboxamide, N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butyl]-4-piperidyl]- 5-[2-[3-oxo-2-[(lRS)-2-oxo-l-phenyl-2-(2-pyridylamino)ethyl]isoindolin-5-yl]ethynyl]pyridine- 2-carboxamide, and
N-[l-[4-[[2-[(3RS)-2,6-Dioxo-3-piperidyl]-l,3-dioxo-isoindolin-4-yl]amino]butyl]-4-piperidyl]- 5-[2-[2-[(lRS)-l-(5-fluoro-2-hydroxy-phenyl)-2-oxo-2-(thiazol-2-ylamino)ethyl]-3-oxo- isoindolin-5-yl]ethynyl]pyridine -2-carboxamide.
6. The compound according to any one of claims 1-5 for use as a medicament.
7. The compound according to any one of claims 1-5, or pharmaceutically acceptable salts thereof, for the therapeutic and/or prophylactic treatment of cancer.
8. Use of the compound according to any one of claims 1-5, or pharmaceutically acceptable salts thereof, for the therapeutic and/or prophylactic treatment of cancer.
9. A pharmaceutical composition comprising a compound according to any one of claims 1-5, and a therapeutically inert carrier.
Figure imgf000043_0001
PCT/EP2019/052585 2018-02-05 2019-02-04 Compounds which cause degradation of egfr, for use against cancer Ceased WO2019149922A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP19702906.9A EP3749664A1 (en) 2018-02-05 2019-02-04 Compounds which cause degradation of egfr, for use against cancer
JP2020541782A JP2021525219A (en) 2018-02-05 2019-02-04 Compounds that cause the degradation of EGFR for use in cancer
CN201980009141.0A CN111615512A (en) 2018-02-05 2019-02-04 Compounds that cause EGFR degradation for anticancer
US16/984,987 US20200361930A1 (en) 2018-02-05 2020-08-04 Bifunctional molecules that degrade egfr

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18155128.4 2018-02-05
EP18155128 2018-02-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/984,987 Continuation US20200361930A1 (en) 2018-02-05 2020-08-04 Bifunctional molecules that degrade egfr

Publications (1)

Publication Number Publication Date
WO2019149922A1 true WO2019149922A1 (en) 2019-08-08

Family

ID=61163580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/052585 Ceased WO2019149922A1 (en) 2018-02-05 2019-02-04 Compounds which cause degradation of egfr, for use against cancer

Country Status (7)

Country Link
US (1) US20200361930A1 (en)
EP (1) EP3749664A1 (en)
JP (1) JP2021525219A (en)
CN (1) CN111615512A (en)
AR (1) AR114244A1 (en)
TW (1) TW201945357A (en)
WO (1) WO2019149922A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
WO2020257607A1 (en) * 2019-06-21 2020-12-24 Dana-Farber Cancer Institute, Inc. Allosteric egfr inhibitors and methods of use thereof
WO2021123087A1 (en) * 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Egfr inhibitors
WO2021127561A1 (en) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
WO2021123084A1 (en) * 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Egfr inhibitors
EP3953332A1 (en) 2019-04-12 2022-02-16 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
WO2022171123A1 (en) 2021-02-10 2022-08-18 Beigene, Ltd. Egfr degraders and methods of use
WO2022270994A1 (en) 2021-06-25 2022-12-29 한국화학연구원 Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
WO2023088385A1 (en) 2021-11-17 2023-05-25 浙江同源康医药股份有限公司 Compound for degrading egfr protein and use thereof
WO2024235289A1 (en) 2023-05-17 2024-11-21 浙江同源康医药股份有限公司 Compound used for egfr protein degradation, and use thereof
WO2024246838A1 (en) 2023-05-31 2024-12-05 Beigene Switzerland Gmbh Compounds for the degradation of egfr kinase
US12391671B2 (en) 2019-11-11 2025-08-19 Dana-Farber Cancer Institute, Inc. Allosteric EGFR inhibitors and methods of use thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN118108706A (en) 2017-09-04 2024-05-31 C4医药公司 Glutarimide
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADATION AND DEGRADATION AGENTS FOR TARGETED PROTEIN DEGRADATION
AU2021231898A1 (en) 2020-03-05 2022-10-27 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
CN119013270A (en) * 2022-04-29 2024-11-22 西藏海思科制药有限公司 Nitrogen-containing heterocyclic derivative, composition thereof and pharmaceutical application thereof
CN115109055B (en) * 2022-05-26 2023-11-28 北京康辰药业股份有限公司 Difunctional compound for EGFR degradation and application thereof
CN115160311B (en) * 2022-05-26 2024-03-15 北京康辰药业股份有限公司 Difunctional compound for EGFR degradation and application thereof
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013020557A1 (en) 2011-08-08 2013-02-14 Syddansk Universitet Method and antibodies for the identification of ubiquitinated proteins and sites of ubiquitination
WO2013063560A2 (en) 2011-10-27 2013-05-02 New York University INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION
WO2013106643A2 (en) 2012-01-12 2013-07-18 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016011906A1 (en) 2014-07-23 2016-01-28 中国科学院上海巴斯德研究所 Use of ubiquitination pathway-related factors in regulating function of t helper cell
US20160176916A1 (en) * 2014-12-23 2016-06-23 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017004383A1 (en) * 2015-06-30 2017-01-05 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017117473A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional molescules for her3 degradation and methods of use
WO2017185036A1 (en) 2016-04-22 2017-10-26 Dana Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
WO2017197036A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197046A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197055A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013020557A1 (en) 2011-08-08 2013-02-14 Syddansk Universitet Method and antibodies for the identification of ubiquitinated proteins and sites of ubiquitination
WO2013063560A2 (en) 2011-10-27 2013-05-02 New York University INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION
WO2013106643A2 (en) 2012-01-12 2013-07-18 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016011906A1 (en) 2014-07-23 2016-01-28 中国科学院上海巴斯德研究所 Use of ubiquitination pathway-related factors in regulating function of t helper cell
US20160176916A1 (en) * 2014-12-23 2016-06-23 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017004383A1 (en) * 2015-06-30 2017-01-05 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017117473A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional molescules for her3 degradation and methods of use
WO2017185036A1 (en) 2016-04-22 2017-10-26 Dana Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
WO2017197036A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197046A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197055A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLLINS ET AL., BIOCHEM J, vol. 474, no. 7, 2017, pages 1127 - 47
ZHOU ET AL.: "Novel mutant-selective EGFR kinase inhibitors against EGFR T790M", NATURE, vol. 462, no. 7276, 24 December 2009 (2009-12-24), pages 1070 - 1074, XP055053374, ISSN: 0028-0836, DOI: doi:10.1038/nature08622

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
EP4470618A2 (en) 2019-03-06 2024-12-04 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
EP3953332A1 (en) 2019-04-12 2022-02-16 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
WO2020257607A1 (en) * 2019-06-21 2020-12-24 Dana-Farber Cancer Institute, Inc. Allosteric egfr inhibitors and methods of use thereof
US12377080B2 (en) 2019-06-21 2025-08-05 Dana-Farber Cancer Institute, Inc. Allosteric EGFR inhibitors and methods of use thereof
US12391671B2 (en) 2019-11-11 2025-08-19 Dana-Farber Cancer Institute, Inc. Allosteric EGFR inhibitors and methods of use thereof
JP7701360B2 (en) 2019-12-20 2025-07-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト EGFR inhibitors
CN114867531A (en) * 2019-12-20 2022-08-05 豪夫迈·罗氏有限公司 EGFR inhibitors
EP4681715A3 (en) * 2019-12-20 2026-01-28 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
EP4681715A2 (en) 2019-12-20 2026-01-21 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
JP2023506809A (en) * 2019-12-20 2023-02-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト EGFR inhibitor
JP2023507311A (en) * 2019-12-20 2023-02-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト EGFR inhibitor
JP2023509375A (en) * 2019-12-20 2023-03-08 シーフォー セラピューティクス， インコーポレイテッド Isoindolinone and indazole compounds for the degradation of EGFR
US12486290B2 (en) 2019-12-20 2025-12-02 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of EGFR
EP4076450A4 (en) * 2019-12-20 2024-01-10 C4 Therapeutics, Inc. ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR EGFR DEGRADATION
CN114867531B (en) * 2019-12-20 2024-03-22 豪夫迈·罗氏有限公司 EGFR inhibitors
JP7757284B2 (en) 2019-12-20 2025-10-21 シーフォー セラピューティクス， インコーポレイテッド Isoindolinone and indazole compounds for degradation of EGFR
JP7737991B2 (en) 2019-12-20 2025-09-11 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト EGFR inhibitor
WO2021123087A1 (en) * 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Egfr inhibitors
WO2021127561A1 (en) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
WO2021123084A1 (en) * 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Egfr inhibitors
US12371442B2 (en) 2019-12-20 2025-07-29 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of EGFR
WO2022171123A1 (en) 2021-02-10 2022-08-18 Beigene, Ltd. Egfr degraders and methods of use
US12161722B2 (en) 2021-06-25 2024-12-10 Korea Research Institute Of Chemical Technology Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof
WO2022270994A1 (en) 2021-06-25 2022-12-29 한국화학연구원 Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
WO2023088385A1 (en) 2021-11-17 2023-05-25 浙江同源康医药股份有限公司 Compound for degrading egfr protein and use thereof
WO2024235289A1 (en) 2023-05-17 2024-11-21 浙江同源康医药股份有限公司 Compound used for egfr protein degradation, and use thereof
WO2024246838A1 (en) 2023-05-31 2024-12-05 Beigene Switzerland Gmbh Compounds for the degradation of egfr kinase

Also Published As

Publication number Publication date
JP2021525219A (en) 2021-09-24
US20200361930A1 (en) 2020-11-19
CN111615512A (en) 2020-09-01
AR114244A1 (en) 2020-08-12
TW201945357A (en) 2019-12-01
EP3749664A1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
WO2019149922A1 (en) Compounds which cause degradation of egfr, for use against cancer
CN110325528B (en) 2-benzopyrazinyl-N-heteroaryl-2-phenyl-acetamide compounds
TWI833773B (en) Compounds
EP3728251A1 (en) Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
CA2875799C (en) Pyrimidinyl tyrosine kinase inhibitors
CN113072542B (en) ROR gamma t inhibitor and preparation method and application thereof
CA3079617A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
KR20190038616A (en) TLR7 / 8 antagonists and their uses
WO2018045956A1 (en) Benzimidazole compound kinase inhibitor, preparation method therefor and application thereof
CA3056833A1 (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
CA3031073A1 (en) N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
TR201814885T4 (en) Heterocyclic compound.
EP3807261B1 (en) Pyridinyl pyrazoles as modulators of roryt
CN103097375A (en) Cyclohexyl-azetidinyl antagonists of CCR2
CN110248949B (en) Immunoproteasome inhibitors
CN105745209A (en) Triazolopyridine compounds, compositions and methods of use
JP2022521453A (en) Heterocyclic derivative
KR20220162159A (en) N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl)acetamide derivatives as SSTR4 agonists
CN110753691B (en) Compounds for therapeutic and/or preventive treatment of cancer
JP7034942B2 (en) Pyrazole derivatives, their compositions and therapeutic uses
JP2022553284A (en) Inhibitors of TREK (TWIK-related K+ channels) channel function
US20250154150A1 (en) Substituted fused ring compound, pharmaceutical composition thereof, preparation method therefor and uses thereof
CA2804924C (en) Substituted pyridine compound
HK40029737A (en) Compounds which cause degradation of egfr, for use against cancer
HK40027513A (en) Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19702906

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020541782

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019702906

Country of ref document: EP

Effective date: 20200907